Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
RESPONSE TO ELECTION/RESTRICTION
Applicant's election with traverse of the compound Example 2C at page 55 of the disclosure and depression as the disease in the reply filed on 9/25/2026 is acknowledged. The traversal is on the ground(s) that the requirement is not the most efficient or expeditious way to proceed in terms of examiner. While the examiner not necessarily agreeing with this statement, the species requirement is hereby withdrawn.
An action on the merits of claims 1-17 is contained herein.
Priority
This application is a continuation of and claims priority to U.S. Application
18/078,389, filed December 9, 2022, which is a Continuation Application of U.S. Application 17/146,608, filed January 12, 2021, (now U.S. Patent No. 11,560,379, issued January 24, 2024), which is a Continuation Application of U.S. Application 16/984,914, filed August 4, 2020 (now U.S. Patent No. 11,370,789 issued June 28, 2022), which is a Divisional Application of U.S. Application 16/382,474, filed April 12, 2019 (now U.S. Patent No. 10,787,449, issued September 29, 2020), which is a Divisional Application of U.S. Application 16/161,642, filed October 16, 2018 (now U.S. Patent No. 10,323,034, issued June 18, 2019), which is a Continuation of U.S. Application No. 16/036,001, filed July 16, 2018, which is a Continuation
Application of U.S. Application No. 14/549,885, filed November 21, 2014 (now U.S. Patent No. 10,047,082, issued August 14, 2018), which claims priority to and the benefit of U.S. Provisional Application Nos. 61/985,035, filed April 28, 2014, and 61/908,333, filed November 25, 2013.
Information Disclosure Statement
The examiner has considered the references cited in the information disclosure statement filed of record.
Specification
Applicant is reminded of the proper content of an Abstract of the Disclosure, see MPEP 608.01(b).
In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, e.g., "The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics." Exemplification of a species could be illustrative of members of the class. For processes, the type reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary.
It is recommended that the structure of Formula I be inserted into the abstract to accurately illustrate the claimed invention.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.
Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).
Claims 1-17 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12, 14, and 16-17 of US Patent 10,047,082. Although the conflicting claims are not identical, they are not patentably distinct from each other because there is significant overlap between the two applications.
The claims of ‘082 provide for a compound of formula I and compositions thereof. ‘082 claims differ from the instant claims only insofar as they are directed to compounds per se and not explicitly directed to a method of treating a depressive disorder.
In the specification of ’082, the patentee discloses that the claimed compounds are therapeutically effective for the treatment of depression generally (column 23, lines 23-26).
A patent’s “disclosure may be used…to answer the question whether claims merely define an obvious variation of what is earlier disclosed and claimed.” AbbVie v. Mathilda & Terence Kennedy Inst. of Rheumatology Trust, 112 USPQ2d 1001, 1012 (Fed. Cir. 2014)(quoting In re Bassell Poliolefine Italia S.P.A., 892 USPQ2d 1030, 1036 (Fed. Cir. 2008)). The AbbVie court explicitly noted that the Federal Circuit has “repeatedly approved examination of the disclosed utility of the invention claimed in an earlier patent to address the question of obviousness” and that “a later expiring patent is not patentably distinct from an earlier expiring patent if it merely claims a disclosed utility of the earlier claimed invention.” Id. For example, when the claims in a later-expiring patent “merely recite methods of administering” the compositions claimed in the earlier patent, they are not patentably distinct over the claims of the earlier expiring patent.” Id. (quoting Pfizer, Inc. v. Teva Pharms. USA. Inc., 86 USPQ2d 1001, 1008 (Fed. Cir. 2008)). See also Sun Pharms. Indus. Ltd. v. Eli Lilly & Co., 95 USPQ2d at 1798, 1803, in which the reference patent claimed a composition and merely remarked in passing on its “excellent oncolytic activity,” and the court held that this disclosure should have compelled a double patenting rejection in a later-filed application claiming methods of using that composition to treat cancer.
Claims 1-7,9-15, and 17 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-2 of US Patent 11,560,379. Although the conflicting claims are not identical, they are not patentably distinct from each other because there is significant overlap between the two applications for the reasons cited above in US Patent 10,047,082 (see col. 23, lines 39-42 of patent ‘379 in this scenario for intended use).
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624